Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. The company is headquartered in Conshohocken, Pennsylvania and currently employs 16 full-time employees. The company went IPO on 2023-10-11. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The company is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
Dr. Raza Bokhari es el Executive Chairman de Medicus Pharma Ltd, se unió a la empresa desde 2023.
¿Qué tal es el rendimiento del precio de la acción MDCX?
El precio actual de MDCX es de $0.3307, ha disminuido un 0.57% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Medicus Pharma Ltd?
Medicus Pharma Ltd pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Medicus Pharma Ltd?
La capitalización bursátil actual de Medicus Pharma Ltd es $13.0M
¿Es Medicus Pharma Ltd una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 6 analistas han realizado calificaciones de análisis para Medicus Pharma Ltd, incluyendo 2 fuerte compra, 6 compra, 1 mantener, 0 venta, y 2 fuerte venta
